{"disease":{"id":"covid-19-prevention","name":"COVID-19 prevention","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":13,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"famtozinameran-12-years-of-age-and-older","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famtozinameran 12 Years of age and older","generic_name":"famtozinameran-12-years-of-age-and-older","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"monoclonal antibody","quality_score":42,"revenue":"4367","mechanism":"Famtozinameran works by targeting the SARS-CoV-2 virus."},{"drug_id":"bnt162b2","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2","generic_name":"bnt162b2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose and a twelfth dose administered at least 2 months after the eleventh dose","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","generic_name":"bivalent-bnt162b2-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with certain immunocompromised individuals","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b5-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b5-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":56,"revenue":null,"mechanism":"Targets the SARS-CoV-2 virus to prevent and treat COVID-19"},{"drug_id":"bnt162b2-omi-jn-1","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi JN.1)","generic_name":"bnt162b2-omi-jn-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"bnt162b4-15-mcg","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b4 15 mcg","generic_name":"bnt162b4-15-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-2025-2026-formulation","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (2025/2026 formulation)","generic_name":"bnt162b2-2025-2026-formulation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 OMI","generic_name":"bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b4-5-mcg","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b4 5 mcg","generic_name":"bnt162b4-5-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"qirv-22-23","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV (22/23)","generic_name":"qirv-22-23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b5-bivalent-wt-omi-ba-2","indication_name":"COVID-19 prevention in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (WT/OMI BA.2)","generic_name":"bnt162b5-bivalent-wt-omi-ba-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"raxtozinameran-6-months-to-4-years-of-age","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Raxtozinameran 6 months to 4 years of age","generic_name":"raxtozinameran-6-months-to-4-years-of-age","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"viral entry inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"bnt162b4-10-mcg","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b4 10 mcg","generic_name":"bnt162b4-10-mcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"combination-bnt162b2-and-bnt162b2-omi","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combination BNT162b2 and BNT162b2 OMI","generic_name":"combination-bnt162b2-and-bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":"A combination of two mRNA-based vaccines that work together to prevent and treat COVID-19."},{"drug_id":"xbb-1-5-adapted-vaccinated","indication_name":"COVID-19 prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"XBB.1.5-adapted vaccinated","generic_name":"xbb-1-5-adapted-vaccinated","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":35,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":54,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04530396","title":"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":33758,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT04741061","title":"Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT04908722","title":"A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1609,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04436276","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1085,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04858633","title":"Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT05091307","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":861,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05007080","title":"A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04713488","title":"An Open Study on the Safety, Tolerability, and Immunogenicity of \"Sputnik Light\" Vaccine","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT04765384","title":"A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05437029","title":"Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Kenneth Palmer","has_results":false},{"nct_id":"NCT05122260","title":"PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Kenneth Palmer","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}